
|Articles|April 12, 2018 (Updated: November 15, 2020)
Ipsos Healthcare Releases Pan-Cancer Testing Monitor in Australia
Advertisement
Ipsos Healthcare-the global healthcare business of Ipsos-announced the expansion of its syndicated Pan-Cancer Testing Monitor (PCTM) to the Australian market.
The study gathers insights from medical oncologists and pathologists on topics such as awareness and current utilization of pan-cancer tests, perceived advantages and disadvantages, and drivers and barriers to use. In addition, it incorporates de-identified patient record forms for patients who were recently tested with a pan-cancer test.
Newsletter
Lead with insight with the Pharmaceutical Executive newsletter, featuring strategic analysis, leadership trends, and market intelligence for biopharma decision-makers.
Advertisement
Advertisement
Advertisement
Trending on PharmExec
1
Technological Renaissance: AI’s Integration into the Pharmaceutical Industry
2
Novo Nordisk Invests $506 Million in Ireland Manufacturing Facility Expansion
3
FDA's History with Complex Plants
4
Patent Term Extension: Challenges with Defining and Claiming Approved Biologics
5




